Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 274

1.

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2015 Dec 2. doi: 10.1038/nature16158. [Epub ahead of print] No abstract available.

PMID:
26633630
2.

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C.

BMC Cancer. 2015 Jul 5;15:499. doi: 10.1186/s12885-015-1505-5.

3.

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.

Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, Callens C, Lidereau R, Bièche I.

Br J Cancer. 2015 Mar 17;112(6):1059-66. doi: 10.1038/bjc.2015.60.

PMID:
25742469
4.

The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.

El-Hage P, Petitalot A, Monsoro-Burq AH, Maczkowiak F, Driouch K, Formstecher E, Camonis J, Sabbah M, Bièche I, Lidereau R, Lallemand F.

Mol Cancer Res. 2015 May;13(5):902-12. doi: 10.1158/1541-7786.MCR-14-0180. Epub 2015 Feb 12.

PMID:
25678599
5.

PIK3R1 underexpression is an independent prognostic marker in breast cancer.

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, Bièche I.

BMC Cancer. 2013 Nov 14;13:545. doi: 10.1186/1471-2407-13-545.

6.

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.

Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.

PMID:
23974829
7.

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas.

Rème T, Hugnot JP, Bièche I, Rigau V, Burel-Vandenbos F, Prévot V, Baroncini M, Fontaine D, Chevassus H, Vacher S, Lidereau R, Duffau H, Bauchet L, Joubert D.

PLoS One. 2013 Jun 21;8(6):e66574. Print 2013.

8.

Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.

Bieche I, Pennaneach V, Driouch K, Vacher S, Zaremba T, Susini A, Lidereau R, Hall J.

Int J Cancer. 2013 Dec 15;133(12):2791-800. doi: 10.1002/ijc.28304. Epub 2013 Aug 9.

9.

TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.

Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA.

Mol Carcinog. 2014 Oct;53(10):807-19. doi: 10.1002/mc.22038. Epub 2013 May 9.

PMID:
23661506
10.

Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.

Hassanein M, Huiart L, Bourdon V, Rabayrol L, Geneix J, Nogues C, Peyrat JP, Gesta P, Meynard P, Dreyfus H, Petrot D, Lidereau R, Noguchi T, Eisinger F, Extra JM, Viens P, Jacquemier J, Sobol H.

Pathobiology. 2013;80(5):219-27. doi: 10.1159/000339432. Epub 2013 Apr 23.

11.

miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.

Lerebours F, Cizeron-Clairac G, Susini A, Vacher S, Mouret-Fourme E, Belichard C, Brain E, Alberini JL, Spyratos F, Lidereau R, Bieche I.

Int J Cancer. 2013 Oct 1;133(7):1614-23. doi: 10.1002/ijc.28171. Epub 2013 Apr 13.

12.

microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I.

Int J Cancer. 2013 Jun 1;132(11):2479-91. doi: 10.1002/ijc.27949. Epub 2013 Feb 25.

13.

Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness.

Dardenne E, Pierredon S, Driouch K, Gratadou L, Lacroix-Triki M, Espinoza MP, Zonta E, Germann S, Mortada H, Villemin JP, Dutertre M, Lidereau R, Vagner S, Auboeuf D.

Nat Struct Mol Biol. 2012 Nov;19(11):1139-46. doi: 10.1038/nsmb.2390. Epub 2012 Sep 30.

PMID:
23022728
14.

Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.

Gaildrat P, Krieger S, Di Giacomo D, Abdat J, Révillion F, Caputo S, Vaur D, Jamard E, Bohers E, Ledemeney D, Peyrat JP, Houdayer C, Rouleau E, Lidereau R, Frébourg T, Hardouin A, Tosi M, Martins A.

J Med Genet. 2012 Oct;49(10):609-17. doi: 10.1136/jmedgenet-2012-100965. Epub 2012 Sep 7.

PMID:
22962691
15.

Identification of new candidate therapeutic target genes in triple-negative breast cancer.

Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I.

Genes Cancer. 2012 Jan;3(1):63-70. doi: 10.1177/1947601912449832.

16.

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.

Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C; kConFab, Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM; Dutch Belgium UV Consortium, Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer, Caputo S, Sinilnikova OM, Lidereau R; French COVAR group collaborators, Couch FJ, Guidugli L, Hansen Tv, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA Consortium.

J Med Genet. 2012 Aug;49(8):525-32.

17.

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frénay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J; GENEPSO, Lidereau R, Andrieu N.

Breast Cancer Res. 2012 Jul 3;14(4):R99. doi: 10.1186/bcr3218.

18.

Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L, Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.

J Bone Miner Res. 2012 Nov;27(11):2387-98. doi: 10.1002/jbmr.1686.

19.

A methodological approach to unravel organ-specific breast cancer metastasis.

Nola S, Sin S, Bonin F, Lidereau R, Driouch K.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):135-45. doi: 10.1007/s10911-012-9256-2. Epub 2012 May 25. Review.

PMID:
22628182
20.

Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKCι/λ overexpression is an independent prognostic factor.

Awadelkarim KD, Callens C, Rossé C, Susini A, Vacher S, Rouleau E, Lidereau R, Bièche I.

Int J Cancer. 2012 Dec 15;131(12):2852-62. doi: 10.1002/ijc.27600. Epub 2012 May 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk